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Management and Care of Women
With Invasive Cervical Cancer:
American Society of Clinical
Oncology Resource-Stratified
Clinical Practice Guideline Summary
Linus T. Chuang, MD, Sarah Temin, MSPH, and Jonathan S. Berek, MD
The purpose of the recently published
ASCO guideline1 is to provide expert
guidance to clinicians and policymakers
in all resource settings on the work-up,
treatment, and palliative care for women
diagnosed with invasive cervical cancer.
There are large disparities in incidence and
mortality regionally and globally regarding
cervical cancer, resulting in part from dis-
parities in the provision of mass screening
(separate ASCO resource-stratified guide-
lines will provide guidance on vaccina-
tion and screening). Treatment of cervical
cancer is dependent on stage of disease.
Treatment may include surgical treat-
ments such as conization, extrafascial or
radical hysterectomy, radiation therapy,
and/or chemotherapy. Different regions of
the world, both among and within coun-
tries, differ with respect to access to these
treatments. Inparticular, regionswith lower
resources tend to have poorer screening
programs, and patients present with more
advanced disease that requires either radi-
cal surgery or chemoradiotherapy, neither
of which is readily available in these
areas. For this reason, standard guide-
lines that assume ideal availability of
surgery and radiotherapy may not be
applicable. The goal of this guideline is to
recommend options in settings in which
ideal treatment regimens may not be
available.
Approximately 85%of incident cervical
cancers occur in less developed regions
(also known as low- and middle-income
countries) around the world, representing
12% of women’s cancers in those regions.
Eighty-seven percent of deaths resulting
from cervical cancer occur in these less
developed regions.2 Some of the regions in
the world with the highest mortality rates
include the WHO South-East Asia and
Western Pacific regions, followed by India
and Africa.2 As a result of these disparities,
the ASCO Resource-Stratified Guidelines
Advisory Group chose cervical cancer as a
priority topic for guideline development.
Disparities exist not only among coun-
tries and global regions but also within
countries. For example, within the United
States, some regions have higher incidences
of cervical cancer (eg, Texas, 9.2; Arkansas,
9.8; andMississippi,9.7per100,000women)3
aswell as rates of poverty greater than 17%.4
In the United States, black women expe-
rience higher incidence of and mortality
from cervical cancer than women of other
races or ethnicities.3 Awareness of these
disparities in access to care should be
considered in the context of this clinical
practice guideline, and health care providers
should strive to deliver the highest level of
cancer care to all women.
ASCO has established a process for
resource-stratifiedguidelines,whichincludes
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THE BOTTOM LINE
Recommendations for the Management and Care of Women With Invasive Cervical Cancer: American
Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline
Guideline Question
In basic-, limited-, enhanced-, and maximal-resource settings, what are the appropriate care options for women
diagnosed with invasive cervical cancer?
Target Population
Women at all levels of resource settings diagnosed with invasive cervical cancer.
Target Audience
This clinical practice guideline globally targets health care providers (including gynecologic oncologists, medical
oncologists, radiation oncologists, obstetricians and gynecologists, surgeons, nurses, and palliative care clinicians),
policymakers, patients, and caregivers.
Methods
A multinational, multidisciplinary expert panel was convened to develop clinical practice guideline recommendations
based on a systematic review of the medical literature and/or an expert consensus process.
Author’s Note.
It is the view of the American Society of Clinical Oncology (ASCO) that health care providers and health care system
decision makers should be guided by the recommendations for the highest stratum of resources available. ASCO
guidelines are intended to complement but not replace local guidelines.
Key Points*
• If follow-up is available, the expert panel recommends cone biopsy for women with stage IA2 disease in basic
settings and cone biopsy plus pelvic lymphadenectomy in limited settings. In enhanced and maximal settings,
radical trachelectomy is recommended for patients with stage IB1 cervical cancer with tumor size up to 2 cmwho
desire fertility-sparing surgery.
• In basic settings where patients cannot be treated with radiation therapy, extrafascial hysterectomy either alone or
after chemotherapy may be an option for women with stage IA1 to IVA cervical cancer.
• In basic settings, for women with larger tumors or advanced-stage cervical cancer, neoadjuvant chemotherapy is
recommended whenever chemotherapy is available, for the purpose of shrinking the tumor before performing
hysterectomy.
• Concurrent radiotherapy and chemotherapy is standard in enhanced andmaximal settings for women with stage
IB to IVA disease.
• The panel stresses the addition of low-dose chemotherapy during radiotherapy, but not at the cost of delaying
radiation therapy if chemotherapy is not available.
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mixed methods of guideline development, adaptation of the
clinical practice guidelines developed by experts on behalf of
organizations, and formal expert consensus. This guideline sum-
marizes the results of that process and presents resource-stratified
recommendations for areas in low- andmiddle-income countries
basedonexistingguidelinesandformalconsensus for thework-up,
care, and palliation of women with invasive cervical cancer.
ThisASCOguideline1 reinforces selected recommendations
offered in the Canadian Cancer Care Ontario (CCO),5,6 Eu-
ropean Society of Medical Oncology,7 Japan Society of Gy-
necologic Oncology,8 US National Comprehensive Cancer
Network,9 and multinational WHO10 guidelines and acknowl-
edges the effort put forth by the authors and aforementioned
societies to produce evidence-based and/or consensus-based
guidelines for women with invasive cervical cancer. In de-
veloping resource-stratified guidelines, ASCO has adopted its
framework from the four-tier approach (basic, limited, enhanced,
and maximal) developed by the Breast Health Global Initiative
and modifications to that framework based on the Disease
Control Priorities 3 and used an evidence-based approach to
inform guideline recommendations.11-13
WORK-UP
The purpose of work-up is to assess a patient’s overall health
status and gather data to inform treatment.Modalities include
history and physical examination, biopsies, blood tests, and
imaging. Tests available inmaximal settings, such asmagnetic
resonance imaging or positron emission tomography–
computed tomography, are optional.
TREATMENT
The treatment of invasive cervical cancer consists of surgery,
chemotherapy,andradiationtherapy,sometimesincombination.
Selected treatment recommendations for women with stage IA1
to IV disease are discussed in the guideline summary bottom
line box.
THE BOTTOM LINE
• In limited-resource settings where there is no brachytherapy, the ASCO expert panel recommends extrafascial
hysterectomy or its modification for women who have residual tumor 2 to 3 months after concurrent
chemoradiotherapy and additional boost.
• For patients with stage IV or recurrent cervical cancer, single-agent chemotherapy (carboplatin or cisplatin) is
recommended in basic settings.
• If the resources are available and the patient cannot receive treatment with curative intent, palliative radiotherapy
should be used to relieve symptoms of pain and bleeding.
• Where resources are constrained, single- or short-course radiotherapy schemes can be used with retreatments if
feasible for persistent or recurrent symptoms.
Qualifying Statements
ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care and that all
patients should have the opportunity to participate.
Palliative care and painmanagement are part of the treatment of cancers, including cervical cancer, to avoid unnecessary
suffering during the final stages of disease. Pain control is a vital component of palliative care, a basic human right often
neglected in cancer control programs.
Additional Resources
More information, including a Data Supplement with additional evidence tables, a Methodology Supplement with
information about evidence quality and strength of recommendations, slide sets, and clinical tools and resources, is
available at www.asco.org/rs-cervical-cancer-treatment-guideline. Patient information is available at www.cancer.net.
(*) Not all recommendations for all settings are listed. Please see Tables 3 to 7 in full guideline.1
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FOLLOW-UP
The ASCO expert panel concluded that there is insufficient
evidence to guide follow-up in all resource settings, especially
those that are resource constrained.ASCOinformally endorsed a
Canadian CCO guideline on follow-up for cervical cancer6 and
provides similar intervals as a guide.
PALLIATIVE CARE
Women with advanced cervical cancer with or without access
to tumor-directed therapy may have specific late-stage symp-
toms that require clinicians to perform urogenital-specific in-
terventions. This guideline adapts guidance on palliative care
provided inaWHOguideline10 onwomenwith cervical cancer.
The management of primary symptoms, which is discussed in
the WHO guideline, includes but is not limited to addressing
pain, fistula, loss of appetite, wasting, bleeding, and gastroin-
testinal and genitourinary symptoms. The ASCO guideline1
also discusses specific measures to address these symptoms.
Inaddition, theASCOguideline1 explores cost implications,
radiation therapy shortages, and the importance of ongoingand
future research. Additional information on the guideline and
themethods of its development is available at www.asco.org/
rs-cervical-cancer-treatment-guideline.
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